Houston fintech startup selected for award-winning program

big start

This Houston-based couple used their own experience of paying down consumer debt to launch a new company. Image courtesy of SpenDebt

Kiley and Ty'Lisha Summers once found themselves nearly $100,000 in debt; now, they have a goal of owning a $100 million company. The Houston-based couple used their own experience of paying down consumer debt to launch SpenDebt, a SaaS payment solution chosen for the Mastercard Start Path program.

You could say debt is ubiquitous in the United States. A 2015 report by The Pew Charitable Trusts found that 80 percent of American households have some form of debt. "As we started sharing our story, we realized that there were so many people who were just like us but didn't know what to do," explains Ty'Lisha, co-founder of SpenDebt.

SpenDebt's model relies on the simple truth: everyone spends money. The company, which is available as a phone app or web service, securely links to the user's bank account and allows you to designate a predetermined micropayment to be deducted at every transaction. The micropayments are then applied monthly to the debt of the user's choice, whether it be lofty student loans or a monthly car payment.

"God gave my husband the vision to start SpenDebt to help people help themselves," she says. Kiley even decided to share his concept Mastercard, but the idea was too early to gain anything other than the corporation's intrigue.

After two years of development and a subsequent year of beta testing, SpenDebt launched its commercialized product in 2019. The Summers applied to Mastercard Start Path, a highly competitive startup engagement program multiple times before being accepted into its 2021 cohort of six scaling startups.

"To finally get the 'yes,' it just made it full circle," says Ty'Lisha. "It's a game changer for SpenDebt."

Ty'Lisha Summers is the co-founder of SpenDebt. Photo courtesy

Fintech is a multibillion-dollar industry, and financial apps have become the darlings of venture capitalism. According to a SpenDebt release, companies that have participated in Start Path have gone on to raise more than $3 billion in post-program capital. Even while investor budgets were trimmed during the pandemic, Fintech companies garnered $44 billion in investments — a 14 percent increase since 2019, reports Finextra.

From the New Statesman to the Raconteur, media outlets and pundits have explored the saturation of the fintech sector. Ty'Lisha is confident that SpenDebt is different from its competitors.

"What's unique is that we give our customers 100 percent control on defining what that micropayment is, unlike our competition where it is strictly just round-up," she explains. The average SpenDebt user has set a $1.70 micropayment, but the co-founders have seen payments set at anything from 50 cents to $25 per transaction.

Initiatives like Bank of America's Keep the Change rounds up each transaction to the nearest dollar amount, then puts that money into a savings account for you to pay your debt off — or not. McKinsey & Company survey reports that more than 50 percent of US consumers expect to spend extra as COVID-19 restrictions relax, with higher-income millennials intending to spend the most. According to CNBC, Gen Z shoppers are also predicted to spend big on niceties like clothing and travel.

Though no app can automate personal discipline, SpenDebt can help you pay down debt and build financial literacy.

"With SpenDebt, once you tell us where you want that payment to go, that's where it's going," explains Ty'Lisha. When the micropayments are deducted from your account, SpenDebt holds onto your accrued payments and sends them monthly to the creditor of your choice. Ty'Lisha notes the service can be canceled or put on hold.

NBC News reported that 46 percent of Americans wiped out their emergency funds in 2020 as they shuffled to make ends meet. States around the country, including Texas, even enacted moratoriums on utility shut-offs in response to the pandemic. In some industries, "businesses went from collecting full payments from people to not collecting anything" or accepting partial payments, she explains.

The pandemic highlighted an opportunity for SpenDebt to partner with enterprises to offer creative solutions for payments that help customers pay off existing debt while helping businesses collect "something versus nothing."

As SpenDebt includes enterprises in its long-term growth strategy, the company founders have also pledged to work with nonprofits.

For the Summerses, SpenDebt's mission surpasses their desire to live a debt-free life. "As a part of our debt-free journey, we couldn't help but become more well-versed in finances. We were on a quest to make our money work for us versus the other way around," shares Ty'Lisha.

As Black business owners, Kiley and Ty'Lisha want to focus on building generational wealth for their family's future and help SpenDebt users do the same. "We like to say that we want all of the generational curses that may have been passed down to us to stop with us, and to start creating generational wealth for our future," she explains.

"[Debt] doesn't just address the middle class; there are so many people across the spectrum in debt," says Ty'Lisha. "A lot of times, the low-to-moderate income communities get overlooked," she continues.

SpenDebt is a preferred partner of United Way of Greater Houston and recently penned a partnership with Impact Hub Houston — an incubator with a mission to empower entrepreneurs and small businesses to take on issues like sustainability, gender equality, and economic growth.

SpenDebt hopes to capture its first enterprise customer during its six-month StartPath program and hopes to one day become a $100 billion company. "The resources, the network, the knowledge that we're getting from Mastercard and their network, the exposure that we're getting—it's going to be huge," says Ty'Lisha.

Of the many goals for SpenDebt's future, she wants the company to be "a solution for communities that may have been overlooked."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings